Short-Term Interest in Agile Therapeutics, Inc. (NASDAQ:AGRX) Drops 88.5%
Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) was the target of a sharp drop in short-term interest during the month of April. As of April 30, there was short interest totaling 286,900 shares, down 88.5% from the April 15 total of 2,500,000 shares. Based on an average daily trading volume of 312,300 shares, the short interest ratio is currently 0.9 days.
A number of large investors have recently bought and sold shares of the company. First Citizens Bank & Trust Co. bought a new position in shares of Agile Therapeutics during the first quarter for a value of approximately $42,000. Renaissance Technologies LLC increased its stake in Agile Therapeutics by 341.6% during the fourth quarter. Renaissance Technologies LLC now owns 162,900 shares of the specialty pharmaceutical company worth $80,000 after acquiring an additional 126,015 shares during the period. Virtu Financial LLC increased its stake in Agile Therapeutics by 771.4% during the fourth quarter. Virtu Financial LLC now owns 237,642 shares of the specialty pharmaceutical company worth $116,000 after acquiring an additional 210,370 shares during the period. GSA Capital Partners LLP increased its stake in Agile Therapeutics by 25.1% during the fourth quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company worth $358,000 after acquiring an additional 147,194 shares during the period. Finally, BlackRock Inc. increased its stake in Agile Therapeutics by 2.5% during the fourth quarter. BlackRock Inc. now owns 1,507,654 shares of the specialty pharmaceutical company worth $736,000 after acquiring 37,394 additional shares during the period. 27.96% of the shares are held by institutional investors.
AGRX has been the subject of a number of research analyst reports. Maxim Group downgraded Agile Therapeutics from a “buy” rating to a “hold” rating in a Friday, April 8 report. Zacks Investment Research upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a Tuesday, May 3, research report. Finally, StockNews.com launched coverage on Agile Therapeutics stocks in a research report on Thursday, May 5. They set a “sell” rating for the company. One equity research analyst rated the stock with a sell rating, two issued a hold rating and two assigned the company a buy rating. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $100.40.
Agile Therapeutics stock traded down $0.14 during Wednesday’s trading, hitting $1.65. 320 shares of the company were traded, against an average volume of 239,174. The company’s 50-day moving average is $9.80 and its two-hundred-day moving average is $16.78. Agile Therapeutics has a 52-week minimum of $1.64 and a 52-week maximum of $69.60. The company has a market capitalization of $6.05 million, a price-earnings ratio of -0.06 and a beta of 1.57.
Agile Therapeutics (NASDAQ:AGRX – Get Rating) last reported quarterly results on Wednesday, March 30. The specialty pharmaceutical company reported ($8.00) earnings per share for the quarter, missing analyst consensus estimates of ($6.80) by ($1.20). Agile Therapeutics recorded a negative return on equity of 376.29% and a negative net margin of 1,825.82%. The company posted revenue of $1.51 million for the quarter, versus $1.58 million for analysts. During the same period last year, the company posted ($8.00) earnings per share. As a group, research analysts expect Agile Therapeutics to post an EPS of -14.8 for the current fiscal year.
About Agile Therapeutics (Get a rating)
Agile Therapeutics, Inc, a women’s healthcare company, researches, develops and markets prescription contraceptive products for women in the United States. Its flagship product is Twirla, also known as AG200-15, a once-weekly prescription combined hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four withdrawal bleeding episodes per year; AG200-15 smaller patch (SmP), which is a treatment regimen designed to provide shorter, lighter withdrawal bleeding and improved contraceptive efficacy; AG200-15 ER SmP, a regimen that allows a woman to extend her contraceptive cycle length, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who cannot or do not want to take estrogen.
Get news and reviews for Agile Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Agile Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.